BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wakefield D, El-asrar AA, Mccluskey P. Treatment of Severe Inflammatory Eye Disease in Patients of Reproductive Age and during Pregnancy. Ocular Immunology and Inflammation 2012;20:277-87. [DOI: 10.3109/09273948.2012.684736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Khong EWC, Chan HHL, Watson SL, Lim LL. Pregnancy and the eye. Curr Opin Ophthalmol 2021;32:527-35. [PMID: 34605446 DOI: 10.1097/ICU.0000000000000778] [Reference Citation Analysis]
2 Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol 2014;2014:401915. [PMID: 24683491 DOI: 10.1155/2014/401915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
3 Chiam NPY, Hall AJH, Stawell RJ, Busija L, Lim LLP. The course of uveitis in pregnancy and postpartum. Br J Ophthalmol 2013;97:1284-8. [DOI: 10.1136/bjophthalmol-2013-303358] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
4 Cordero-coma M, Salazar-méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opinion on Drug Safety 2015;14:1071-86. [DOI: 10.1517/14740338.2015.1044969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Roy M. Analysis of uveitis in a Canadian aboriginal population. Canadian Journal of Ophthalmology 2014;49:128-34. [DOI: 10.1016/j.jcjo.2013.09.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kryshtalskyj MT, Roy M. Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population. Ocul Immunol Inflamm 2021;:1-7. [PMID: 33621146 DOI: 10.1080/09273948.2020.1849737] [Reference Citation Analysis]
7 Papotto PH, Marengo EB, Sardinha LR, Carvalho KI, de Carvalho AE, Castillo-Mendez S, Jank CC, Vanhove B, Goldberg AC, Rizzo LV. Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS One 2017;12:e0171822. [PMID: 28248972 DOI: 10.1371/journal.pone.0171822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Wakefield D, McCluskey P, Wildner G, Thurau S. Unmet Needs and Future Directions in Inflammatory Eye Disease. Ocul Immunol Inflamm 2017;25:122-33. [PMID: 27070178 DOI: 10.3109/09273948.2016.1151897] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Van Bentum RE, Van den Berg JM, Wolf SE, Van der Bijl J, Tan HS, Verbraak FD, van der Horst-Bruinsma IE. Multidisciplinary management of auto-immune ocular diseases in adult patients by ophthalmologists and rheumatologists. Acta Ophthalmol 2021;99:e164-70. [PMID: 32749781 DOI: 10.1111/aos.14548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wakefield D, McCluskey P, Wildner G, Thurau S, Carr G, Chee SP, Forrester J, Dick A, Hudson B, Lightman S, Smith J, Tugal-Tutkun I; pre-treatment assessment Review panel. Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmun Rev 2017;16:213-22. [PMID: 28137477 DOI: 10.1016/j.autrev.2017.01.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]